ROCKVILLE, Md., Sept. 5,
2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced it will participate in the following upcoming
investor conferences:
Morgan Stanley 21st Annual Global Healthcare
Conference
Fireside Chat Date: Tuesday, September 12, 2023
Fireside Chat Time: 10:10 a.m.
ET
Location: New York, NY
2023 Baird Global Healthcare Conference
Fireside
Chat Date: Wednesday, September 13,
2023
Fireside Chat Time: 9:40 a.m.
ET
Location: New York, NY
A live webcast of the fireside chats can be accessed in the
Investors section of REGENXBIO's website at www.regenxbio.com. An
archived replay of the webcast will be available for approximately
30 days following the presentation.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a
proprietary adeno-associated virus (AAV) gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its
third-party NAV Technology Platform Licensees are applying the NAV
Technology Platform in the development of a broad pipeline of
candidates, including late-stage and commercial programs, in
multiple therapeutic areas. REGENXBIO is committed to a
"5x'25" strategy to progress five AAV Therapeutics from our
internal pipeline and licensed programs into pivotal-stage or
commercial products by 2025.
Contacts:
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301916241.html
SOURCE REGENXBIO Inc.